Pharmacotherapeutics of tourette syndrome and stereotypies in autism

Seminars in Pediatric Neurology

Volumn 17, Issue 4, 2010, Pages 254-260

  Rajapakse, Thilinie ^a   Pringsheim, Tamara ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CITALOPRAM; CLONIDINE; DOCOSAHEXAENOIC ACID; ETIRACETAM; GUANFACINE; HALOPERIDOL; ICOSAPENTAENOIC ACID; METOCLOPRAMIDE; OMEGA 3 FATTY ACID; ONDANSETRON; PENTOXIFYLLINE; PLACEBO; RISPERIDONE; TOPIRAMATE;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ADJUVANT THERAPY; AGGRESSION; AGITATION; ANXIETY; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; AUTISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEART CONDUCTION; HUMAN; HYPERACTIVITY; HYPERKINESIA; HYPERSALIVATION; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LETHARGY; LIVER FUNCTION TEST; MENTAL CONCENTRATION; MENTAL DETERIORATION; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; OBSESSIVE COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STEREOTYPY; TIC; TREMOR; VERBAL HOSTILITY; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEREOTYPIC MOVEMENT DISORDER; TOURETTE SYNDROME;

EID: 78650273397     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2010.10.008     Document Type: Review

References (27)

1. Pringsheim T., Lang A., Kurlan R., et al. Understanding disability in Tourette syndrome. Dev Med Child Neurol 2009, 51:468-472.
2. American Psychiatic Association, Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, Text Revision. 4th edition.
3. Scahill L., Erenberg G., Berlin C.M., et al. Contemporary assessment of pharmacotherapy of Tourette syndrome. Neurorx 2006, 2:192-206.
4. Sethi K., Morgan J. Drug-induced movement disorders. Parkinson's Disease and Movement Disorders 2007, 394-408. Lippincott Williams and Wilkins, Philadelphia. J. Jankovic, E. Tolosa (Eds.).
5. Wolf D.S., Singer H.S. Pediatric movement disorders: An update. Curr Opin Neurol 2008, 21:491-496.
6. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the U.S. Preventive Services Task Force a review of the process. Am J Prev Med 2001, 20:21-35.
7. Leckman J.F., Riddle M.A., Hardin M.T., et al. Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989, 28:566-573.
8. Guy W. Clinical global impressions, in ECDEU Assessment Manual for Psychopharmacology, Revised 1976, 217-222. Dept of Health, Education, and Welfare, National Institute of Mental Health, Rockville, MD.
9. Smith-Hicks C.L., Bridges D.D., Paynter N.P., et al. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764-1767.
10. Hedderick E.F., Morris C.M., Singer H.S. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009, 40:420-425.
11. Nicolson R., Craven-Thuss B., Smith J., et al. A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourettes disorder. J Am Acad Child Adolesc Psychiatry 2005, 44:640-646.
12. Spencer T.J., Sallee F.R., Gilbert D.L. Atmoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008, 11:470-481.
13. Wang R., Lagakos S.W., Ware J.H., et al. Statistics in medicine-Reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357:2189-2194.
14. Jankovic J., Jimenez-Shahed J., Brown L.W. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010, 81:70-73.
15. Toren P., Weizman A., Ratner S., et al. Ondansetron treatment in Tourette's disorder: A 3 week, randomized, double-blind, placebo controlled study. J Clin Psychiatry 2005, 66:499-503.
16. Jesner O.S., Aref-Adib M., Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007, 1. CD005040.
17. Pandina G.J., Bossie C.A., Youssef E., et al. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007, 37:367-373.
18. Miral S., Gencer O., Baykara B., et al. Risperidone versus haloperidol in children and adolescents with AD: A randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008, 17:1-8.
19. Akhondzadeh S., Fallah J., Mohammadi M., et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:32-36.
20. Marcus R.N., Owen R., Kame L., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48:1110-1119.
21. Owen R., Sikich L., Marcus R.N., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
22. Amminger G.P., Berger G.E., Schäfer M.R., et al. Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007, 61:551-553.
23. King B.H., Hollander E., Sikich L., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66:583-590.
24. Arnold L.E., Aman M.G., Cook A.M., et al. Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006, 45:1196-1205.
25. Wasserman S., Iyengar R., Chaplin W.F., et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006, 21:363-367.
26. Handen B.L., Sahl R., Hardan A.Y. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 2008, 29:303-308.
27. Correll C.U., Manu P., Olshanskiy V., et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 28:765-773.